Embarc

Bison Capital Acquisition Corp

Merged
CIK: 1697805•Ticker: BCAC
Successfully merged with Xynomic Pharmaceuticals, Inc.

SPAC Overview

$52.5M
IPO Size
$1.1K
Trust (as of 2019-12-31)
Completed
Current Status
2017
IPO Year

Timeline Progress

About

Bison Capital Acquisition Corp. is a blank-check company seeking to acquire an unidentified business. It intends to focus on companies with primary operations in Asia and North America in media/entertainment, consumer services, and healthcare.

Investment Focus

Entertainment, Media, Consumer, Healthcare

Geographic Focus

Asia, North America

Embarc dashboard

What the sponsor registered, what the deal actually priced at, and every 8-K that moved it — unit structure, sponsor promote, and the dated lifecycle events, each linked to its filing.

  • Unit structure as registered and as priced — price, warrant coverage, rights, trust per unit
  • Sponsor promote: founder shares and percentage, private-placement warrants, trust deposit
  • The full 8-K lifecycle timeline, each event linked to its filing
  • Price history across the unit, share and warrant tickers
  • Follow it, and see it change on your watchlist
Open in the dashboard

SPAC Team

Sponsors

Bison Capital Holding

Leadership

Peixin Xu
Chairman of the Board of Directors, President
Yinglin Mark Xu
Chairman of the Board of Directors, Chairman, CEO & President, Chief Executive Officer, Interim Chief Financial Officer, President
James Jiayuan Tong
Chief Executive Officer, Chief Financial Officer, Director
Jiayuan James Tong
Chief Strategy Officer, Executive Director, Executive Vice President
Jinwei Coco Kou
Interim Chief Accounting Officer
Peng Jin
Chief Operating Officer, Secretary
Sophia Paspal
Chief Development Officer
Wentao Jason Wu
Chief Operating Officer
Ying Zhang
VP of Global Strategic Sourcing
Adam Inglis
Independent Director
Charles Vincent Prizzi
Director, Independent Director
Ning Wang
Director
Richard Peidong Wu
Independent Director
Thomas Folinsbee
Director, Independent Director
Tingzhi Qian
Executive Director
Yong Cui
VP of Chemistry, Manufacturing, and Controls (CMC) and Director
Fengyun Jiang
Beneficial owner

Extended Team Information

The management team includes financial services and accounting professionals, senior operating executives, and directors of Asian and North American companies with M&A and cross-border investment experience. Its sponsor, Bison Capital, is an investment firm with advisory, investing, and funds-management capabilities.

Key Information

IPO Date
June 21, 2017
Total Redemptions
$8.4M
PIPE
$7.7M
State of Incorporation
D8
SIC
6770
Completion Date
May 15, 2019
Merger Target
Xynomic Pharmaceuticals, Inc.
SPAC Ticker
BCAC

External Resources

SEC Filings
View Detailed Analysis